SABS

SAB Biotherapeutics (SABS)

SAB Biotherapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SABS

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/06	20 : 15	GlobeNewswire Inc.	SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/04/16	20 : 15	GlobeNewswire Inc.	SAB Biotherapeutics Provides SAB-142 Trial Update	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/04/08	20 : 15	GlobeNewswire Inc.	SAB Biotherapeutics to Present at INNODIA Annual Meeting	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/04/04	20 : 15	GlobeNewswire Inc.	SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/03/29	20 : 15	GlobeNewswire Inc.	SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/03/25	23 : 15	GlobeNewswire Inc.	SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/03/09	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/02/24	06 : 55	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/02/24	06 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/02/23	22 : 00	GlobeNewswire Inc.	SAB Biotherapeutics to Present at the BIO CEO & Investor Conference	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/02/08	22 : 00	GlobeNewswire Inc.	SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/02/02	21 : 53	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/02/02	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Executive Leadership Change	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/27	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/27	06 : 00	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/26	07 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/24	07 : 58	GlobeNewswire Inc.	SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/20	06 : 21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/03	23 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/03	06 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/12/18	23 : 34	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/12/09	07 : 26	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/12/01	07 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/29	21 : 40	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/29	21 : 30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/29	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/29	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/29	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/23	06 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/21	07 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc